Key statistics dashboard for Cingulate Inc. (CING). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine).
Stock Data
| Price | $5.09 |
| Market Cap | $69M |
| Beta | -0.77 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.02 |
| Price / Book | 1.19 |
| P/S | 0.00 |
| P/FCF | -3.30 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 3.50 |
| Quick Ratio | 3.50 |
| Cash Ratio | 3.29 |
| Debt / Equity | 0.27 |
| Debt / Assets | 19.03% |
| Interest Coverage | 20.43 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 4.32 |
| Cash per share | 5.23 |
| FCF per share | -3.86 |
| Tangible Book Value per share | 4.32 |
| Dividend per share | 0.00 |
Related companies: ALLR · BCTX · CASI · CLSD · ENTO · KAPA · LEXX
Explore sector: Healthcare · Biotechnology
More sections of CING: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks